Markets:

Overview

News

Currencies

International

Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

45.00 +0.56 (+1.26%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2 ↗

October 02, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some medical stock opportunities...

Via Talk Markets

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

Stocks That Made New Highs On Friday, Aug. 19 ↗

August 21, 2022

On Friday, in spite of the stock market being down, there were several stocks that actually made new highs.

Via Talk Markets

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 25, 2022

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients ↗

May 02, 2022

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Looking Into Supernus Pharmaceuticals's Return On Invested Capital ↗

April 14, 2022

According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million.

Via Benzinga

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗

April 07, 2022

On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.

Via Investor's Business Daily

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last? ↗

February 21, 2022

Supernus Pharmaceuticals shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session.

Via Talk Markets

Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)

January 24, 2022

Via AB Newswire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

SUPN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Supernus Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2021

Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Why Supernus' Acquisition of Adamas Is a Smart Move ↗

October 21, 2021

Adamas looks like a good fit for Supernus.

Via The Motley Fool

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...

Via Talk Markets

Topics Stocks

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...

Via Benzinga

Topics Stocks

Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals ↗

October 11, 2021

Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...

Via Benzinga

Topics Stocks

ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News ↗

October 11, 2021

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million.

Via InvestorPlace

Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights ↗

October 11, 2021

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal...

Via Benzinga

Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization ↗

August 16, 2021

Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What...

Via Benzinga

Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript ↗

August 04, 2021

SUPN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For August 4, 2021 ↗

August 04, 2021

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

All News about Supernus Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today